Skip to content

A trial to learn how baxdrostat affects the heartbeat in healthy participants

Status
Completed
Phases
Phase 1
Study type
Interventional
Source
EU CTIS
Registry ID
CTIS2023-506108-23-00
Acronym
D6970C00004
Enrollment
28
Registered
2024-01-30
Start date
2024-02-06
Completion date
2024-05-13
Last updated
2024-04-24

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Primary aldosteronism, Treatment-resistant hypertension, Uncontrolled hypertension

Interventions

None listed

Sponsors

Astrazeneca AB
Lead SponsorINDUSTRY

Eligibility

Sex/Gender
All
Age
18 Years to 64 Years

Countries

Germany

Outcome results

None listed

Source: EU CTIS · Data processed: Feb 4, 2026